Clinical and biological features of favorable-risk acute myelogenous leukemia - is favorable-risk AML really favorable?

被引：1
|
作者：
Schiller, GJ [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
来源：
LEUKEMIA | 2005年 / 19卷 / 03期
关键词：
D O I：
10.1038/sj.leu.2403659
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：326 / 328
页数：3
相关论文
共 50 条
  • [1] Clinical and biological features of favorable-risk acute myelogenous leukemia – is favorable-risk AML really favorable?
    G J Schiller
    Leukemia, 2005, 19 : 326 - 328
  • [2] Is Favorable-Risk AML Always Favorable?
    Dillon, Richard
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S3 - S4
  • [3] Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia
    Strickland, Stephen A.
    Shaver, Aaron C.
    Byrne, Michael
    Daber, Robert D.
    Ferrell, P. Brent
    Head, David R.
    Mohan, Sanjay R.
    Mosse, Claudio A.
    Moyo, Tamara K.
    Stricker, Thomas P.
    Vnencak-Jones, Cindy
    Savona, Michael R.
    Seegmiller, Adam C.
    LEUKEMIA RESEARCH, 2018, 65 : 67 - 73
  • [4] Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)
    Arslan, Shukaib
    Zhang, Jianying
    Dhakal, Prajwal
    Moran, Jenna A.
    Naidoo, Nuthana
    Story, Jennifer Lombardi
    Pullarkat, Vinod A.
    Stein, Anthony S.
    Marcucci, Guido
    Yaghmour, George
    Bhatt, Vijaya R.
    Fathi, Amir T.
    Aldoss, Ibrahim
    BLOOD, 2020, 136
  • [5] Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy
    Tavitian, Suzanne
    Denis, Amelia
    Vergez, Francois
    Berard, Emilie
    Sarry, Audrey
    Huynh, Anne
    Delabesse, Eric
    Luquet, Isabelle
    Huguet, Francoise
    Recher, Christian
    Bertoli, Sarah
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (02) : 193 - 198
  • [6] Genotypic and Clinical Heterogeneity Amongst NCCN Favorable-Risk Acute Myeloid Leukemias
    Seegmiller, Adam
    Strickland, Stephen A.
    Shaver, Aaron C.
    Daber, Robert D.
    Byrne, Michael
    Ferrell, P. B.
    Head, David R.
    Mohan, Sanjay R.
    Vnencak-Jones, Cindy L.
    Zutter, Mary M.
    Savona, Michael R.
    LABORATORY INVESTIGATION, 2017, 97 : 375A - 375A
  • [7] Genotypic and Clinical Heterogeneity Amongst NCCN Favorable-Risk Acute Myeloid Leukemias
    Seegmiller, Adam
    Strickland, Stephen A.
    Shaver, Aaron C.
    Daber, Robert D.
    Byrne, Michael
    Ferrell, P. B.
    Head, David R.
    Mohan, Sanjay R.
    Vnencak-Jones, Cindy L.
    Zutter, Maly M.
    Savona, Michael R.
    MODERN PATHOLOGY, 2017, 30 : 375A - 375A
  • [8] Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia
    Arslan, Shukaib
    Zhang, Jianying
    Dhakal, Prajwal
    Moran, Jenna
    Naidoo, Nuthana
    Lombardi, Jennifer
    Pullarkat, Vinod
    Stein, Anthony S.
    Marcucci, Guido
    Yaghmour, George
    Bhatt, Vijaya R.
    Fathi, Amir T.
    Aldoss, Ibrahim
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (03) : E59 - E63
  • [9] Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML)
    Vegunta, Rathnamitreyee
    Harel, Ronen
    Steinberg, Amir
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [10] THE POOR RISK ASSOCIATED WITH TETRAPLOIDY IN AML OVERCOMES FAVORABLE-RISK FEATURES AND WARRANTS A CONSOLIDATION WITH ALLOGENEIC STEM CELL TRANSPLANT
    Berbari, B.
    Jansen, M.
    Behren, M.
    Safah, H.
    Saba, N. S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (02) : 575 - 575
12345